| 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) |
1155 |
| 2018 ESC/ESH Guidelines for the management of arterial hypertension |
1140 |
| 2018 ESC/EACTS Guidelines on myocardial revascularization |
653 |
| 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS |
438 |
| 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) |
356 |
| The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation |
355 |
| 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy |
188 |
| International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology |
156 |
| 2018 ESC Guidelines for the diagnosis and management of syncope |
146 |
| Cardiovascular disease burden from ambient air pollution in Europe reassessed using novel hazard ratio functions |
134 |
| European Society of Cardiology: Cardiovascular Disease Statistics 2017 |
110 |
| How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) |
103 |
| Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans |
85 |
| Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC) |
81 |
| International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management |
76 |
| A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions |
68 |
| Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF |
66 |
| Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) |
65 |
| The hypoxic burden of sleep apnoea predicts cardiovascular disease-related mortality: the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study |
63 |
| A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension |
63 |
| Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction |
63 |
| A new staging system for cardiac transthyretin amyloidosis |
62 |
| European Society of Cardiology, acute cardiovascular care association, SCAD study group: a position paper on spontaneous coronary artery dissection ESC-ACCA Position Paper on spontaneous coronary artery dissection |
61 |
| Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials |
60 |
| Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions |
59 |
| Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials |
58 |
| May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension |
56 |
| Impact of chronic dietary red meat, white meat, or non-meat protein on trimethylamine N-oxide metabolism and renal excretion in healthy men and women |
56 |
| Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis |
53 |
| Impact of treatment delay on mortality in ST-segment elevationmyocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial |
53 |
| Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA) |
52 |
| Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract |
51 |
| Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk |
51 |
| Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study |
50 |
| Management of cardiogenic shock complicating myocardial infarction: an update 2019 |
49 |
| Heart failure with preserved ejection fraction: from mechanisms to therapies |
48 |
| Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data |
48 |
| The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability |
48 |
| Clinical applications of machine learning in cardiovascular disease and its relevance to cardiac imaging |
46 |
| Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification |
46 |
| A population-based study of cardiovascular diseasemortality risk in US cancer patients |
45 |
| Canadian spontaneous coronary artery dissection cohort study: in-hospital and 30-day outcomes |
44 |
| Refining the prognostic impact of functional mitral regurgitation in chronic heart failure |
43 |
| Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrumof heart failure risk in the EMPA-REG OUTCOME (R) trial |
43 |
| Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry |
43 |
| International recommendations for electrocardiographic interpretation in athletes |
42 |
| Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections |
42 |
| Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation |
41 |
| Gut microbial diversity is associated with lower arterial stiffness in women |
40 |
| Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function |
40 |
| Pacemaker implantation rate after transcatheter aortic valve implantation with early and new-generation devices: a systematic review |
40 |
| Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives |
39 |
| Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology |
39 |
| The continuous heart failure spectrum: moving beyond an ejection fraction classification |
39 |
| Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review andmeta-analysis of randomized clinical trials |
39 |
| IL-18 cleavage triggers cardiac inflammation and fibrosis upon beta-adrenergic insult |
38 |
| Coronary computed tomography angiography for heart team decision-making in multivessel coronary artery disease |
38 |
| Patients with acute myocardial infarction and non-obstructive coronary arteries: safety and prognostic relevance of invasive coronary provocative tests |
37 |
| Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial |
37 |
| Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular Interventions |
37 |
| Separate and combined associations of obesity andmetabolic health with coronary heart disease: a pan-European case-cohort analysis |
36 |
| Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients |
36 |
| Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy |
36 |
| Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis |
36 |
| European Association of Preventive Cardiology (EAPC) and European Association of Cardiovascular Imaging (EACVI) joint position statement: recommendations for the indication and interpretation of cardiovascular imaging in the evaluation of the athlete's heart |
35 |
| Cardio-Oncology Services: rationale, organization, and implementation A report from the ESC Cardio-Oncology council |
35 |
| Periprocedural myocardial infarction and injury in elective coronary stenting |
35 |
| Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials |
34 |
| Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve: lessons from the ADVANCE Registry |
34 |
| A novel machine learning-derived radiotranscriptomic signature of perivascular fat improves cardiac risk prediction using coronary CT angiography |
34 |
| Acute aortic syndromes: diagnosis and management, an update |
34 |
| Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective internationalmulti-ethnic cohort study |
33 |
| Incidence, predictors, and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: insights from the VIVID registry |
33 |
| Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction |
33 |
| A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy |
32 |
| Systemic microvascular dysfunction in microvascular and vasospastic angina |
32 |
| Sex differences in heart failure |
32 |
| Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis |
32 |
| Transcatheter mitral valve repair for functional mitral regurgitation using the Cardioband system: 1 year outcomes |
32 |
| Effects of gaseous and solid constituents of air pollution on endothelial function |
31 |
| Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks |
31 |
| N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels |
31 |
| Deep learning for cardiovascular medicine: a practical primer |
30 |
| Asleep blood pressure: significant prognostic marker of vascular risk and therapeutic target for prevention |
30 |
| Outcomes after extracorporeal membrane oxygenation for the treatment of high-risk pulmonary embolism: a multicentre series of 52 cases |
30 |
| Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis |
30 |
| Standardized End Point Definitions for Coronary Intervention Trials |
30 |
| Associations between vascular risk factors and brain MRI indices in UK Biobank |
30 |
| Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction |
30 |
| Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry |
30 |
| Interleukin-1 blockade in cardiovascular diseases: a clinical update |
29 |
| Altered limbic and autonomic processing supports brain-heart axis in Takotsubo syndrome |
29 |
| Plaque erosion: a new in vivo diagnosis and a potentialmajor shift in themanagement of patients with acute coronary syndromes |
29 |
| CRISPR/Cas9 editing in human pluripotent stemcell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy |
29 |
| An autoantibody identifies arrhythmogenic right ventricular cardiomyopathy and participates in its pathogenesis |
27 |
| High lipoprotein(a) and high risk of mortality |
27 |
| Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease |
27 |
| Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a population-based cohort |
27 |
| Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial |
27 |
| Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-termlife-threatening arrhythmias |
27 |
| Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals |
27 |
| Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation |
26 |
| Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial |
26 |
| Serumpotassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortiummeta-analysis |
26 |
| Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial |
26 |
| Diagnostic performance of angiography-derived fractional flow reserve: a systematic review and Bayesian meta-analysis |
26 |
| 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia |
26 |
| Comparison of balloon-expandable vs. self-expandable valves in patients undergoing transfemoral transcatheter aortic valve implantation: from the CENTER-collaboration |
26 |
| Patients at low surgical risk as defined by the Society of Thoracic Surgeons Score undergoing isolated interventional or surgical aortic valve implantation: in-hospital data and 1-year results from the German Aortic Valve Registry (GARY) |
25 |
| Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014 |
25 |
| Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension |
25 |
| Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar |
24 |
| Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, ismodifiable, and associates with future cardiovascular deaths |
24 |
| Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC RegistryOf Pregnancy And Cardiac disease (ROPAC) |
24 |
| The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction |
24 |
| Less dementia with oral anticoagulation in atrial fibrillation |
24 |
| Reduction in radiation exposure in cardiovascular computed tomography imaging: results from the PROspective multicenter registry on radiaTion dose Estimates of cardiac CT angIOgraphy iNdaily practice in 2017 (PROTECTION VI) |
24 |
| Distinct child-to-adult body mass index trajectories are associated with different levels of adult cardiometabolic risk |
24 |
| Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment |
24 |
| European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism |
24 |
| Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference |
24 |
| CXCL1-CXCR2 axismediates angiotensin II-induced cardiac hypertrophy and remodelling through regulation ofmonocyte infiltration |
23 |
| U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies |
23 |
| Prediction of obstructive coronary artery disease and prognosis in patients with suspected stable angina |
23 |
| Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies |
23 |
| Early goal-directed haemodynamic optimization of cerebral oxygenation in comatose survivors after cardiac arrest: the Neuroprotect post-cardiac arrest trial |
23 |
| Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial |
22 |
| Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial |
22 |
| Treatment of cardiac transthyretin amyloidosis: an update |
22 |
| Incidence of device-related infection in 97 750 patients: clinical data from the complete Danish device-cohort (1982-2018) |
22 |
| Causal association between periodontitis and hypertension: evidence from Mendelian randomization and a randomized controlled trial of non-surgical periodontal therapy |
22 |
| The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporarymanagement of adult patients with cardiomyopathies |
22 |
| External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry |
22 |
| Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study |
22 |
| Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation |
22 |
| Crucial role for Nox2 and sleep deprivation in aircraft noise-induced vascular and cerebral oxidative stress, inflammation, and gene regulation |
21 |
| Development of significant tricuspid regurgitation over time and prognostic implications: new insights into natural history |
21 |
| Atrial fibrillation ablation in practice: assessing CABANA generalizability |
21 |
| Expert recommendations on the assessment of wall shear stress in human coronary arteries: existing methodologies, technical considerations, and clinical applications |
21 |
| A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial |
21 |
| Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics |
21 |
| Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial |
21 |
| New-onset left bundle branch block after transcatheter aortic valve replacement is associated with adverse long-term clinical outcomes in intermediate-risk patients: an analysis from the PARTNER II trial |
21 |
| Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: nationwide data covering the entire Korean population |
21 |
| Association of estimated sleep duration and naps with mortality and cardiovascular events: a study of 116 632 people from 21 countries |
21 |
| Differential effects of endurance, interval, and resistance training on telomerase activity and telomere length in a randomized, controlled study |
20 |
| A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation |
20 |
| Big data from electronic health records for early and late translational cardiovascular research: challenges and potential |
20 |
| PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor |
20 |
| Pleiotropic effects of laminar flow and statins depend on the Kruppel-like factor-induced lncRNA MANTIS |
20 |
| Sex differences in calcified plaque and long-term cardiovascular mortality: observations from the CAC Consortium |
20 |
| Association between regional body fat and cardiovascular disease risk among postmenopausal women with normal body mass index |
19 |
| The impact of confounding on the associations of different adiposity measures with the incidence of cardiovascular disease: a cohort study of 296 535 adults of white European descent |
19 |
| Trimethyllysine, a trimethylamine N-oxide precursor, provides near- and long-term prognostic value in patients presenting with acute coronary syndromes |
19 |
| Clinical recommendations for high altitude exposure of individuals with pre-existing cardiovascular conditions |
19 |
| UK Biobank: opportunities for cardiovascular research |
19 |
| Prognostic value of coronary computed tomographic angiography findings in asymptomatic individuals: a 6-year follow-up from the prospective multicentre international CONFIRM study |
19 |
| Transcatheter aortic valve implantation: current status and future perspectives |
19 |
| Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities |
19 |
| Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model |
19 |
| Incidence of complications related to catheter ablation of atrial fibrillation and atrial flutter: a nationwide in-hospital analysis of administrative data for Germany in 2014 |
19 |
| Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization |
19 |
| Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis |
19 |
| Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2) |
18 |
| In vivo predictors of plaque erosion in patients with ST-segment elevation myocardial infarction: a clinical, angiographical, and intravascular optical coherence tomography study |
18 |
| Machine learning algorithms estimating prognosis and guiding therapy in adult congenital heart disease: data from a single tertiary centre including 10019 patients |
18 |
| Infective endocarditis after transcatheter aortic valve implantation: a nationwide study |
18 |
| Recommendations for participation in leisure time or competitive sports in athletes-patients with coronary artery disease: a position statement fromthe Sports Cardiology Section of the European Association of Preventive Cardiology (EAPC) |
18 |
| A meta-analysis of continuous positive airway pressure therapy in prevention of cardiovascular events in patients with obstructive sleep apnoea |
18 |
| Does pregnancy complication history improve cardiovascular disease risk prediction? Findings from the HUNT study in Norway |
18 |
| Acellular therapeutic approach for heart failure: in vitro production of extracellular vesicles from human cardiovascular progenitors |
18 |
| Arrhythmic risk stratification in post-myocardial infarction patients with preserved ejection fraction: the PRESERVE EF study |
18 |
| Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials |
18 |
| A systematic analysis of mutual effects of transportation noise and air pollution exposure on myocardial infarction mortality: a nationwide cohort study in Switzerland |
17 |
| Rate of peri-procedural stroke observed with cerebral embolic protection during transcatheter aortic valve replacement: a patient-level propensity-matched analysis |
17 |
| Improved oral hygiene care attenuates the cardiovascular risk of oral health disease: a population-based study from Korea |
17 |
| Diagnostic and prognostic value of myocardial blood flow quantification as non-invasive indicator of cardiac allograft vasculopathy |
17 |
| Calcific aortic valve stenosis: hard disease in the heart |
17 |
| Retinal microvascular dysfunction in heart failure |
17 |
| Restrictive compared with liberal red cell transfusion strategies in cardiac surgery: a meta-analysis |
17 |
| Reduction of low density lipoprotein- cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration |
17 |
| Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial |
17 |
| Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting |
17 |
| Lower carbohydrate diets and all-cause and cause-specific mortality: a population-based cohort study and pooling of prospective studies |
17 |
| Epidemiology report: trends in sex-specific cerebrovascular disease mortality in Europe based on WHO mortality data |
17 |
| A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score |
17 |
| Causes and mechanisms of isolated mitral regurgitation in the community: clinical context and outcome |
17 |
| No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data |
17 |
| A decade of catheter ablation of cardiac arrhythmias in Sweden: ablation practices and outcomes |
16 |
| Quantifying infective endocarditis risk in patients with predisposing cardiac conditions |
16 |
| Treatments targeting inotropy |
16 |
| Transcatheter aortic valve implantation in lower-risk patients: what is the perspective? |
16 |
| Temporal trends in atrial fibrillation recurrence rates after ablation between 2005 and 2014: a nationwide Danish cohort study |
16 |
| Autologous CD34(+) cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials |
16 |
| Frailty and related outcomes in patients undergoing transcatheter valve therapies in a nationwide cohort |
16 |
| Single-cell transcriptome analyses reveal novel targetsmodulating cardiac neovascularization by resident endothelial cells following myocardial infarction |
16 |
| Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol |
16 |
| The Reducer device in patients with angina pectoris: mechanisms, indications, and perspectives |
16 |
| Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials |
15 |
| Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France |
15 |
